GSK’s B7H3, IDRx-42 Progress Spurs 2,500p Price Target
GSK•An investment bank flagged four near-term catalysts in GSK's oncology pipeline and maintained a buy rating with a 2,500p price target. GSK will present B7H3 antibody-drug conjugate datasets in H2 2026, plans multiple Phase III trials, and accelerates IDRx-42 Phase III initiation.
1. Reaffirmed Buy Rating and Price Target
An investment bank reaffirmed a buy rating on GSK with a 2,500p price target, highlighting four near-term catalysts that could drive valuation ahead of several upcoming data releases.
2. B7H3 and B7H4 Pipeline Updates
GSK will share new B7H3 antibody-drug conjugate datasets in H2 2026, targeting thoracic, gastrointestinal, prostate and sarcoma tumours, while its B7H4 programme remains focused on ovarian and endometrial cancers, with multiple Phase III trials slated.
3. IDRx-42 and Blenrep Developments
GSK’s IDRx-42 gastrointestinal stromal tumour therapy showed lower grade 3 adverse events versus competitors and is being fast-tracked into Phase III first-line trials, and Blenrep modelling suggests a median progression-free survival of 100 months in a triplet regimen.
4. AI, M&A and Long-Term Oncology Outlook
Management emphasised the need for external M&A to complement internal R&D, highlighted organoid technology acquired via a 2025 purchase, and projected oncology to significantly contribute to sales by 2031, underpinned by AI and digital pathology.
